Skip to main content
Premium Trial:

Request an Annual Quote

Shares in Nanogen Surge 21 Percent on News of FDA Clearance

NEW YORK, March 29 (GenomeWeb News) - Shares in Nanogen were up 21.11 percent, or $.57, at $3.27 in mid-afternoon trading after the company this morning said it won 510(k) clearance from the US Food and Drug Administration to sell one of its tests.

 

The product, called StatusFirst CHFNT-proBNP EDTA plasma test, is used to diagnose individuals suspected of having congestive heart failure. It is the first 510(k) clearance for Nanogen.

 

Nanogen said it will continue developing its StatusFirst CHF whole blood test with an eye for FDA clearance.

 

The cleared test is the result of a collaboration between Nanogen and Princeton BioMeditech Corporation. The companies co-developed and will co-market the product, Nanogen said.

 

PBM will manufacture the product under contract with Nanogen. The test is sold in conjunction with the DXpress reader, a qualitative and quantitative instrument supplied by PBM.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.